Apellis Pharmaceuticals is a biopharmaceutical company that focuses on developing and commercializing therapeutic compounds to treat autoimmune and inflammatory diseases. They are currently conducting Phase III clinical trials for their lead product candidate, pegcetacoplan, which can be used to treat age-related macular degeneration and paroxysmal nocturnal hemoglobinuria. The company is also developing other drugs to treat various neurology, hematology, and nephrology disorders.